Neuartige Kombination von Pozelimab und Cemdisiran (Poze-Cemdi) erreicht bessere Kontrolle der intravaskulären Hämolyse bei Patienten mit Paroxysmaler nächtlicher Hämoglobinurie im Vergleich zu Ravulizumab.
The ongoing registrational cohort is investigating poze-cemdi against eculizumab, another standard-of-care C5 inhibitor. The study is expected to enroll approximately 200 patients with PNH who have previously received eculizumab. The primary endpoint is the proportion of patients who achieve LDH normalization over 26 weeks. Results from this cohort are anticipated in 2025. Overall, the positive … Weiterlesen